September 2026 - Reduction Activity drug patent information, international generic entry, market access

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	9,327,028	⤷ Start Trial				⤷ Start Trial
Apotex	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	8,722,738	⤷ Start Trial				⤷ Start Trial
Apotex	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	8,148,356	⤷ Start Trial	Y			⤷ Start Trial
Apotex	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alvogen	ACETYLCYSTEINE	acetylcysteine	SOLUTION;INHALATION, ORAL	203853-001	Jun 21, 2012	AN	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 17, 2026

“Reduction activity” is a broad mechanism label used across multiple therapeutic classes that share one common biochemical theme: drugs that act by reducing a substrate (directly or via redox pathways). Patent estates and market dynamics therefore vary sharply by specific active ingredient and indication. For investment, licensing, and litigation screening, the right approach is to map each reduction-activity active ingredient to (1) its FDA Orange Book status and exclusivity clock, (2) the composition/method-of-use/formulation layers that commonly show up in Orange Book and related patent dockets, and (3) the factual generic entry pathways most likely to trigger Paragraph IV challenges.

This report compiles the actionable framework used to evaluate “reduction activity” drugs at portfolio level, focusing on patent and regulatory levers that govern market exclusion, settlement economics, and generic launch timing.

What patents protect reduction-activity drugs, and what parts of the estate matter most?

Short answer: For reduction-activity drugs, the most litigated and monetized patent layers are usually (1) composition-of-matter for the active ingredient or key analogs, (2) method-of-use for specific indications, patient populations, or dosing regimens, and (3) formulation and manufacturing/process patents that can support exclusivity beyond the earliest composition expiry via non-infringement, inducement, or separate “use in product” protection.

How to segment the patent estate for “reduction activity” mechanisms

A practical portfolio breakdown for reduction-activity products typically includes:

Active ingredient and analog composition
- Core compound(s), key stereoisomers, and salt/solvate variants.
- Dependency: if the active ingredient is off-patent, “evergreening” often shifts to salt/form and combination compositions.
Method-of-use patents
- Indication-specific claims (stage of disease, biomarker-defined subgroups).
- Dosing schedule claims tied to pharmacokinetics or adherence-driven regimens.
Formulation patents
- Controlled release, enteric coating, solubility enhancers, and stability around redox-sensitive moieties.
- Delivery systems: topical, injectable, or inhaled versions that preserve activity and reduce degradation.
Manufacturing and process patents
- Process steps that control impurities generated during reduction chemistry.
- Scale-up methods that reduce yield loss or environmental byproducts.

Which patent types most often block generic “skin-in-the-game” entry?

In reduction-activity drugs, generic challengers often face two recurring barriers:

Redox-sensitive formulation constraints
- If product stability or release kinetics depends on proprietary excipient or processing parameters, a generic may not be able to certify safe equivalence without risking infringement.
Method-of-use claims that survive generic product entry
- Even with a bioequivalent generic, use patents can prevent launch for a protected indication until carve-outs or licensing.

Hurdle map for licensing and infringement theory

Strongest leverage for brand:
- Composition-of-matter covering the actual active ingredient or a narrow salt/solvate used in the approved product.
- Method-of-use for the most commercially material indication.
- Formulation/method-of-manufacture that generic applicants must match beyond typical equivalence.
Strongest leverage for generic:
- Composition expiry with limited Orange Book listings for the approved indication.
- Narrow method-of-use claims that can be designed around by label carve-outs.
- Formulation patents that are easy to avoid by changing manufacturing controls without affecting equivalence.

When does exclusivity end for reduction-activity drugs, and how should you time generic entry?

Short answer: Exclusivity ends in layers: patent expiry can be earlier than regulatory exclusivity; then 180-day exclusivity (if triggered) can extend generic competitive dynamics. For reduction-activity drugs, the practical schedule often hinges on Orange Book-listed patents tied to composition or method-of-use and on whether the drug has regulatory exclusivities such as new chemical entity (NCE) or new molecular entity (RLD) exclusivity, as applicable.

Typical exclusivity timelines to model

For brand cash-flow protection, the “end of exclusivity” timeline is modeled as:

Regulatory exclusivity (if applicable)
- NCE/NME-like exclusivity, pediatric exclusivity extensions, and any additional exclusivity tied to supplements.
Patent expiry
- Earliest expiration among Orange Book-listed patents for the approved drug.
Biosimilar/generic market entry dynamics
- For small molecules, generic entry is usually controlled by patent expiry and Paragraph IV timing.
- For biologics with reduction-activity mechanisms (rare but possible), biosimilar incentives depend on 351(k) exclusivity and biosimilar patent thickets.

Featured-snippet style rule

Generic entry risk increases sharply when the earliest Orange Book-listed patent tied to the approved drug expires and there is no remaining method-of-use protection for the commercial indication.

Portfolio-level timing checklist

Identify the earliest Orange Book expiration for each approved strength and dosage form.
Identify whether later-expiring method-of-use patents cover the specific label indication.
Check whether formulation patents are Orange Book-listed; if not, they may still drive litigation via non-Orange-Book infringement theories.
Model whether first-filer Paragraph IV applicants can capture 180-day exclusivity even if later settlements narrow carve-outs.

How many patents cover reduction-activity drugs on the Orange Book, and what does concentration look like?

Short answer: Orange Book coverage tends to cluster: a small number of patents often account for the largest portion of enforcement leverage. Concentration is usually highest around the active ingredient composition and the method-of-use patents tied to the top revenue indications.

How to quantify coverage in practice

For each reduction-activity drug product, you typically compute:

Number of Orange Book patents
- Count by patent type: composition, method-of-use, and formulation.
Expiration distribution
- Compute weighted median and next-to-expire counts by date.
Claim overlap likelihood
- Where method-of-use is broad, generic design-around probability falls.
Prosecution history and claim narrowing
- Narrow claims can lower risk of generic infringement but can increase the likelihood of procedural disputes.

Where patent estates are most “dense”

New molecular entities with first-line indications often show more method-of-use and formulation layers.
Products with multiple salts/forms or different delivery routes can create cross-coverage that increases the effective number of enforceable patents.
Products that require redox stabilization for shelf life commonly show added manufacturing and formulation patents that are not always obvious from label alone.

Which companies are challenging reduction-activity drugs with Paragraph IV, and what patterns emerge?

Short answer: Paragraph IV challenges typically cluster around (1) products nearing earliest Orange Book expiry and (2) products where brand estates include at least one method-of-use patent that can be attacked via non-infringement or invalidity while still enabling label carve-outs.

Common challenger playbooks

Fast generic launch with carve-out strategy
- Generic files a label that omits the protected indication if method-of-use patents remain.
Settlement-first strategy
- Generic seeks a negotiated launch date and avoids prolonged litigation cost.
Non-infringement pivot
- Generic product design focuses on differences in formulation or dosing that avoid claim scope.

Market impact

When one challenger becomes first filer, it can shape the competitive map even after settlement because:

Co-filers face the settlement terms and carve-outs.
The brand’s litigation posture may shift from “win at all costs” to “reduce injunction risk in exchange for time.”

What is the Orange Book status of reduction-activity drugs, and how does it drive litigation risk?

Short answer: Orange Book status drives the litigation entry vector. The Orange Book determines which patents are asserted for the approved NDA or ANDA listing and therefore shapes Paragraph IV procedural posture and timing.

What to extract from Orange Book listings

NDA/strength/dosage form mapping.
Patent numbers and expiration dates.
Patent type (composition vs method-of-use vs formulation).
Patent scope note: whether patents are tied to the active ingredient or to the approved formulation.

Why Orange Book is not the whole story

Even when a patent is not listed, brand holders can assert it under non-Orange-Book theories, especially for:

Formulation or manufacturing patents with process claim scope.
Method-of-use theories not captured by the Orange Book listing.

Featured-snippet rule: If a reduction-activity drug has limited Orange Book listings but heavy non-listed formulation protection, litigation risk can still remain high.

How strong is the patent estate for reduction-activity drugs, and what predicts enforceability?

Short answer: Patent strength is highest when the estate includes early compound coverage that is hard to design around and when method-of-use claims are broad enough to cover real-world prescribing without carve-outs.

Strength signals used in portfolio diligence

Breadth of claims
- Broad Markush sets and fewer limitations can increase infringement probability.
Claim construction risk
- Narrow dependent claims reduce generic risk but increase invalidity surface area.
Citation and prior art proximity
- Redox chemistry and analog families often have dense prior art, affecting obviousness risk.
Family size and continuations
- Larger families can extend protection even if individual claims are narrowed.

Litigation outcomes that matter commercially

If a court narrows claim scope or invalidates key method-of-use patents, generic design-around becomes viable.
If courts uphold composition coverage, settlement leverage increases and generic launch shifts.

What formulations are protected for reduction-activity drugs, and what generic entry risks exist?

Short answer: Formulation patents often protect stability, controlled release, or redox-sensitive shelf life. Generic entry risk depends on whether generic filers must match specific excipient and manufacturing parameters that could affect reduction-activity drug performance.

Formulation protection categories common to reduction-activity products

Controlled release
- Patents tied to release kinetics to maintain therapeutic redox balance.
Stability and degradation control
- Formulation strategies that prevent degradation of reduction-active compounds.
Bioavailability and absorption control
- Solubilizers and coatings that control rate of onset and exposure.

Design-around risk map

High risk:
- Formulation patents with narrow but specific process steps that are hard to replicate.
- Manufacturing patents involving impurities control that impacts equivalence.
Moderate risk:
- Patents claiming excipient combinations that generic can replace while maintaining bioequivalence.
Low risk:
- Formulation claims that are overbroad at the conceptual level with clear equivalents.

What method-of-use patents protect reduction-activity drugs, and when can brands be carved out?

Short answer: Method-of-use patents protect dosing, patient selection, and disease stage. Carve-outs are usually possible only when claims are indication-specific and the brand can enforce reduced scope through label restrictions rather than product redesign.

Carve-out mechanics

Brand wins full market protection when method-of-use claims cover the entire branded label.
Generic wins faster entry when:
- claims cover narrow biomarker-defined cohorts that the generic can omit from labeling; or
- dosing regimen claims can be avoided through different schedule or titration language.

Litigation friction

Method-of-use litigation tends to create prolonged uncertainty even if composition patents expire earlier because:

infringement depends on how physicians prescribe within the label and on how the court construes “use.”

What patent litigation affects reduction-activity drug launches, and how do settlements alter timelines?

Short answer: Settlement agreements typically define an outside launch date, label carve-outs, and sometimes non-infringement covenants or royalties. Litigation outcome determines whether generics can enter with full label or only partial carve-outs.

Settlement terms that move the market

Launch date
- Often set to a date aligned to the next Orange Book expiration.
Label carve-outs
- Generic avoids protected indications while brand preserves them.
Design modifications
- Generic commits to formulation changes to avoid infringement.
Stipulated injunction
- Brand may withdraw or delay an injunction contingent on settlement compliance.

Business implications

Early settlements reduce litigation spend but can increase total consumer cost if they preserve later-expiring patents.
Delayed settlements can accelerate generic entry if courts narrow claims, reducing brand’s settlement leverage.

How does FDA regulatory status affect market dynamics for reduction-activity drugs?

Short answer: FDA pathway and exclusivity dictate the regulatory feasibility of abbreviated approval and the speed at which generic applications can be filed and approved relative to patent expiry.

Key regulatory levers

Pathway selection
- ANDA with Paragraph IV is the usual mechanism for small-molecule reduction-activity drugs.
Orphan designation or special pediatric exclusivity
- Can alter the exclusivity baseline and extend protection.
Listing in Orange Book
- Controls which patents trigger the Paragraph IV framework.

How do reduction-activity drugs compare with competing mechanisms in patent “cliff risk”?

Short answer: Reduction-activity mechanism classes can have either sharp or gradual exclusivity cliffs depending on how many distinct formulation and method-of-use layers are added to protect redox stability and real-world dosing.

Portfolio comparison logic

Sharp cliff profile
- If the estate is mostly compound-driven and method-of-use/formulation layers expire early, generic pressure builds once composition expires.
Gradual cliff profile
- If formulation and method-of-use patents extend years after compound expiry, generic entry may be delayed or limited to carve-outs.

What to measure

Time from earliest compound expiry to last method-of-use/formulation expiry.
Share of remaining revenue tied to the protected indication(s).
Evidence of ongoing supplements or line extensions that introduce new patents.

Key Takeaways

“Reduction activity” is a mechanism label that spans multiple drug classes; patent and exclusivity analysis must be mapped to each specific active ingredient, product strength, and indication.
The enforceable estate typically clusters in composition-of-matter plus method-of-use and formulation, with manufacturing-process patents increasing risk where redox stability is critical.
Market timing is driven by the earliest Orange Book expiry and whether remaining method-of-use patents allow carve-outs.
Paragraph IV challenges concentrate near expiries and where generic label carve-outs can be achieved without product redesign.
Settlement terms typically set a launch date aligned to the next enforceable patent and use label carve-outs to preserve brand revenue.

FAQs

1) How do formulation patents on reduction-activity drugs change Paragraph IV infringement analyses?
They shift the dispute from simple bioequivalence to product sameness around stability, release kinetics, and manufacturing controls.

2) Can a generic launch for reduction-activity drugs if the composition patent expires but method-of-use patents remain?
Yes, when the generic can omit protected indications through labeling or design around claim scope without infringing method-of-use protection.

3) What does “Orange Book status” reveal about market exclusivity for reduction-activity drugs?
It identifies which patents are tied to the approved NDA/strength/dosage form and therefore governs Paragraph IV timing and litigation assertions.

4) What settlement terms most influence competitive dynamics for reduction-activity drugs?
Outside launch dates, label carve-outs, and any required design or formulation changes that avoid infringement.

5) What indicators suggest a steep exclusivity cliff for a reduction-activity brand?
A heavy dependency on early compound patents with limited later-expiring method-of-use or formulation coverage and few Orange Book-listed patents beyond the initial expiry.

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
U.S. Food and Drug Administration. Drug Approval Packages and Submission Formats. FDA.
FDA. Guidance for Industry: How to Submit a 505(b)(2) Application and Related Information. FDA.
U.S. Patent and Trademark Office. Patent assignment and prosecution resources. USPTO.